Contact
searchSearch
HMP Global

ACTRIMS Meeting Newsroom

Conference Coverage
Study Links MS-Related Fatigue to Disability Status and Lower Quality of Life
03/13/2025
Fatigue in multiple sclerosis is strongly linked to lower quality of life, particularly in those with higher disability scores, and decreased work capacity, according to recent research.
Fatigue in multiple sclerosis is strongly linked to lower quality of life, particularly in those with higher disability scores, and decreased work capacity, according to recent research.
Fatigue in multiple sclerosis is...
03/13/2025
First Report Managed Care
Conference Coverage
Study Examines the Effects of MS Treatment on Mobility and Emergency Care
03/13/2025
A retrospective cohort study presented at the 2025 ACTRIMS Forum challenges conventional assumptions regarding disease-modifying therapies (DMTs) in multiple sclerosis (MS). While DMTs are designed to reduce relapse rates and MRI activity,...
A retrospective cohort study presented at the 2025 ACTRIMS Forum challenges conventional assumptions regarding disease-modifying therapies (DMTs) in multiple sclerosis (MS). While DMTs are designed to reduce relapse rates and MRI activity,...
A retrospective cohort study...
03/13/2025
First Report Managed Care
Conference Coverage
Ozanimod Shows Promise in Preserving Brain Volume in Patients With Early Relapsing MS
03/04/2025
Treatment with ozanimod in patients with early relapsing multiple sclerosis (MS) showed promising results in preserving brain volume over 1 year, potentially slowing down the accelerated brain volume loss seen in patients with MS.
Treatment with ozanimod in patients with early relapsing multiple sclerosis (MS) showed promising results in preserving brain volume over 1 year, potentially slowing down the accelerated brain volume loss seen in patients with MS.
Treatment with ozanimod in...
03/04/2025
First Report Managed Care
Conference Coverage
Immunomodulatory Effects of Modified Atkins Diet in Patients With Multiple Sclerosis
03/04/2025
A study on the effects of a modified Atkins diet in patients with multiple sclerosis reveals significant changes in immune cell metabolism and anti-inflammatory responses, suggesting the potential for dietary interventions in multiple...
A study on the effects of a modified Atkins diet in patients with multiple sclerosis reveals significant changes in immune cell metabolism and anti-inflammatory responses, suggesting the potential for dietary interventions in multiple...
A study on the effects of a...
03/04/2025
First Report Managed Care
Conference Coverage
MSDA Test Helps Guide Multiple Sclerosis Treatment Decisions, Study Finds
02/28/2025
The MS Disease Activity test helps guide treatment decisions in multiple sclerosis based on objective changes in treatment plan and clinician reported impact, according to a study presented at the 2025 ACTRIMS Forum.
The MS Disease Activity test helps guide treatment decisions in multiple sclerosis based on objective changes in treatment plan and clinician reported impact, according to a study presented at the 2025 ACTRIMS Forum.
The MS Disease Activity test...
02/28/2025
First Report Managed Care
Conference Coverage
Study Finds No Treatment Disparities in MS Care Between Medicaid and Private Insurance
02/28/2025
A study presented at the 2025 ACTRIMS Forum shows that individuals with Medicaid receive similar high-efficacy treatment for multiple sclerosis as those with private insurance, supporting Medicaid’s role in promoting health equity.
A study presented at the 2025 ACTRIMS Forum shows that individuals with Medicaid receive similar high-efficacy treatment for multiple sclerosis as those with private insurance, supporting Medicaid’s role in promoting health equity.
A study presented at the 2025...
02/28/2025
First Report Managed Care
Conference Coverage
The Clinical and Economic Burden of Primary Progressive Multiple Sclerosis
02/27/2025
New research highlights the significant health care challenges and costs associated with primary progressive multiple sclerosis (PPMS).
New research highlights the significant health care challenges and costs associated with primary progressive multiple sclerosis (PPMS).
New research highlights the...
02/27/2025
First Report Managed Care
Conference Coverage
Leveraging AI for Multiple Sclerosis Diagnosis
02/27/2025
Researchers tested GPT-4’s ability to classify multiple sclerosis diagnosis from clinical notes, finding promising but imperfect results with 74% overall accuracy.
Researchers tested GPT-4’s ability to classify multiple sclerosis diagnosis from clinical notes, finding promising but imperfect results with 74% overall accuracy.
Researchers tested GPT-4’s...
02/27/2025
First Report Managed Care

Conference Coverage
Study Links MS-Related Fatigue to Disability Status and Lower Quality of Life
03/13/2025
Fatigue in multiple sclerosis is strongly linked to lower quality of life, particularly in those with higher disability scores, and decreased work capacity, according to recent research.
Fatigue in multiple sclerosis is strongly linked to lower quality of life, particularly in those with higher disability scores, and decreased work capacity, according to recent research.
Fatigue in multiple sclerosis is...
03/13/2025
First Report Managed Care
Conference Coverage
Study Examines the Effects of MS Treatment on Mobility and Emergency Care
03/13/2025
A retrospective cohort study presented at the 2025 ACTRIMS Forum challenges conventional assumptions regarding disease-modifying therapies (DMTs) in multiple sclerosis (MS). While DMTs are designed to reduce relapse rates and MRI activity,...
A retrospective cohort study presented at the 2025 ACTRIMS Forum challenges conventional assumptions regarding disease-modifying therapies (DMTs) in multiple sclerosis (MS). While DMTs are designed to reduce relapse rates and MRI activity,...
A retrospective cohort study...
03/13/2025
First Report Managed Care
Conference Coverage
Ozanimod Shows Promise in Preserving Brain Volume in Patients With Early Relapsing MS
03/04/2025
Treatment with ozanimod in patients with early relapsing multiple sclerosis (MS) showed promising results in preserving brain volume over 1 year, potentially slowing down the accelerated brain volume loss seen in patients with MS.
Treatment with ozanimod in patients with early relapsing multiple sclerosis (MS) showed promising results in preserving brain volume over 1 year, potentially slowing down the accelerated brain volume loss seen in patients with MS.
Treatment with ozanimod in...
03/04/2025
First Report Managed Care
Conference Coverage
Immunomodulatory Effects of Modified Atkins Diet in Patients With Multiple Sclerosis
03/04/2025
A study on the effects of a modified Atkins diet in patients with multiple sclerosis reveals significant changes in immune cell metabolism and anti-inflammatory responses, suggesting the potential for dietary interventions in multiple...
A study on the effects of a modified Atkins diet in patients with multiple sclerosis reveals significant changes in immune cell metabolism and anti-inflammatory responses, suggesting the potential for dietary interventions in multiple...
A study on the effects of a...
03/04/2025
First Report Managed Care
Conference Coverage
MSDA Test Helps Guide Multiple Sclerosis Treatment Decisions, Study Finds
02/28/2025
The MS Disease Activity test helps guide treatment decisions in multiple sclerosis based on objective changes in treatment plan and clinician reported impact, according to a study presented at the 2025 ACTRIMS Forum.
The MS Disease Activity test helps guide treatment decisions in multiple sclerosis based on objective changes in treatment plan and clinician reported impact, according to a study presented at the 2025 ACTRIMS Forum.
The MS Disease Activity test...
02/28/2025
First Report Managed Care
Conference Coverage
Study Finds No Treatment Disparities in MS Care Between Medicaid and Private Insurance
02/28/2025
A study presented at the 2025 ACTRIMS Forum shows that individuals with Medicaid receive similar high-efficacy treatment for multiple sclerosis as those with private insurance, supporting Medicaid’s role in promoting health equity.
A study presented at the 2025 ACTRIMS Forum shows that individuals with Medicaid receive similar high-efficacy treatment for multiple sclerosis as those with private insurance, supporting Medicaid’s role in promoting health equity.
A study presented at the 2025...
02/28/2025
First Report Managed Care
Conference Coverage
The Clinical and Economic Burden of Primary Progressive Multiple Sclerosis
02/27/2025
New research highlights the significant health care challenges and costs associated with primary progressive multiple sclerosis (PPMS).
New research highlights the significant health care challenges and costs associated with primary progressive multiple sclerosis (PPMS).
New research highlights the...
02/27/2025
First Report Managed Care
Conference Coverage
Leveraging AI for Multiple Sclerosis Diagnosis
02/27/2025
Researchers tested GPT-4’s ability to classify multiple sclerosis diagnosis from clinical notes, finding promising but imperfect results with 74% overall accuracy.
Researchers tested GPT-4’s ability to classify multiple sclerosis diagnosis from clinical notes, finding promising but imperfect results with 74% overall accuracy.
Researchers tested GPT-4’s...
02/27/2025
First Report Managed Care
Conference Coverage
Study Links MS-Related Fatigue to Disability Status and Lower Quality of Life
03/13/2025
Fatigue in multiple sclerosis is strongly linked to lower quality of life, particularly in those with higher disability scores, and decreased work capacity, according to recent research.
Fatigue in multiple sclerosis is strongly linked to lower quality of life, particularly in those with higher disability scores, and decreased work capacity, according to recent research.
Fatigue in multiple sclerosis is...
03/13/2025
First Report Managed Care
Conference Coverage
Study Examines the Effects of MS Treatment on Mobility and Emergency Care
03/13/2025
A retrospective cohort study presented at the 2025 ACTRIMS Forum challenges conventional assumptions regarding disease-modifying therapies (DMTs) in multiple sclerosis (MS). While DMTs are designed to reduce relapse rates and MRI activity,...
A retrospective cohort study presented at the 2025 ACTRIMS Forum challenges conventional assumptions regarding disease-modifying therapies (DMTs) in multiple sclerosis (MS). While DMTs are designed to reduce relapse rates and MRI activity,...
A retrospective cohort study...
03/13/2025
First Report Managed Care
Conference Coverage
Ozanimod Shows Promise in Preserving Brain Volume in Patients With Early Relapsing MS
03/04/2025
Treatment with ozanimod in patients with early relapsing multiple sclerosis (MS) showed promising results in preserving brain volume over 1 year, potentially slowing down the accelerated brain volume loss seen in patients with MS.
Treatment with ozanimod in patients with early relapsing multiple sclerosis (MS) showed promising results in preserving brain volume over 1 year, potentially slowing down the accelerated brain volume loss seen in patients with MS.
Treatment with ozanimod in...
03/04/2025
First Report Managed Care
Conference Coverage
Immunomodulatory Effects of Modified Atkins Diet in Patients With Multiple Sclerosis
03/04/2025
A study on the effects of a modified Atkins diet in patients with multiple sclerosis reveals significant changes in immune cell metabolism and anti-inflammatory responses, suggesting the potential for dietary interventions in multiple...
A study on the effects of a modified Atkins diet in patients with multiple sclerosis reveals significant changes in immune cell metabolism and anti-inflammatory responses, suggesting the potential for dietary interventions in multiple...
A study on the effects of a...
03/04/2025
First Report Managed Care
Conference Coverage
MSDA Test Helps Guide Multiple Sclerosis Treatment Decisions, Study Finds
02/28/2025
The MS Disease Activity test helps guide treatment decisions in multiple sclerosis based on objective changes in treatment plan and clinician reported impact, according to a study presented at the 2025 ACTRIMS Forum.
The MS Disease Activity test helps guide treatment decisions in multiple sclerosis based on objective changes in treatment plan and clinician reported impact, according to a study presented at the 2025 ACTRIMS Forum.
The MS Disease Activity test...
02/28/2025
First Report Managed Care
Conference Coverage
Study Finds No Treatment Disparities in MS Care Between Medicaid and Private Insurance
02/28/2025
A study presented at the 2025 ACTRIMS Forum shows that individuals with Medicaid receive similar high-efficacy treatment for multiple sclerosis as those with private insurance, supporting Medicaid’s role in promoting health equity.
A study presented at the 2025 ACTRIMS Forum shows that individuals with Medicaid receive similar high-efficacy treatment for multiple sclerosis as those with private insurance, supporting Medicaid’s role in promoting health equity.
A study presented at the 2025...
02/28/2025
First Report Managed Care
Conference Coverage
The Clinical and Economic Burden of Primary Progressive Multiple Sclerosis
02/27/2025
New research highlights the significant health care challenges and costs associated with primary progressive multiple sclerosis (PPMS).
New research highlights the significant health care challenges and costs associated with primary progressive multiple sclerosis (PPMS).
New research highlights the...
02/27/2025
First Report Managed Care
Conference Coverage
Leveraging AI for Multiple Sclerosis Diagnosis
02/27/2025
Researchers tested GPT-4’s ability to classify multiple sclerosis diagnosis from clinical notes, finding promising but imperfect results with 74% overall accuracy.
Researchers tested GPT-4’s ability to classify multiple sclerosis diagnosis from clinical notes, finding promising but imperfect results with 74% overall accuracy.
Researchers tested GPT-4’s...
02/27/2025
First Report Managed Care
Conference Coverage
Preparing for the Future of Neurological Therapies
02/03/2025
Gain insights on navigating the future of neurological therapies from industry experts at the 2025 NeuroNet Pro Annual Summit.
Gain insights on navigating the future of neurological therapies from industry experts at the 2025 NeuroNet Pro Annual Summit.
Gain insights on navigating the...
02/03/2025
First Report Managed Care
Conference Coverage
Data-Driven Neurology: Potential AI Patient Care Innovations
02/03/2025
Panelists at the 2025 NeuroNet Pro Annual Summit delve into the transformative power of artificial intelligence (AI) and collective clinical data in neurology, showcasing how partnerships and advanced technology are reshaping the landscape of...
Panelists at the 2025 NeuroNet Pro Annual Summit delve into the transformative power of artificial intelligence (AI) and collective clinical data in neurology, showcasing how partnerships and advanced technology are reshaping the landscape of...
Panelists at the 2025 NeuroNet...
02/03/2025
First Report Managed Care

What's New?

Conference Coverage
Study Links MS-Related Fatigue to Disability Status and Lower Quality of Life
03/13/2025
Fatigue in multiple sclerosis is strongly linked to lower quality of life, particularly in those with higher disability scores, and decreased work capacity, according to recent research.
Fatigue in multiple sclerosis is strongly linked to lower quality of life, particularly in those with higher disability scores, and decreased work capacity, according to recent research.
Fatigue in multiple sclerosis is...
03/13/2025
First Report Managed Care
Conference Coverage
Study Examines the Effects of MS Treatment on Mobility and Emergency Care
03/13/2025
A retrospective cohort study presented at the 2025 ACTRIMS Forum challenges conventional assumptions regarding disease-modifying therapies (DMTs) in multiple sclerosis (MS). While DMTs are designed to reduce relapse rates and MRI activity,...
A retrospective cohort study presented at the 2025 ACTRIMS Forum challenges conventional assumptions regarding disease-modifying therapies (DMTs) in multiple sclerosis (MS). While DMTs are designed to reduce relapse rates and MRI activity,...
A retrospective cohort study...
03/13/2025
First Report Managed Care
Conference Coverage
Ozanimod Shows Promise in Preserving Brain Volume in Patients With Early Relapsing MS
03/04/2025
Treatment with ozanimod in patients with early relapsing multiple sclerosis (MS) showed promising results in preserving brain volume over 1 year, potentially slowing down the accelerated brain volume loss seen in patients with MS.
Treatment with ozanimod in patients with early relapsing multiple sclerosis (MS) showed promising results in preserving brain volume over 1 year, potentially slowing down the accelerated brain volume loss seen in patients with MS.
Treatment with ozanimod in...
03/04/2025
First Report Managed Care
Conference Coverage
Immunomodulatory Effects of Modified Atkins Diet in Patients With Multiple Sclerosis
03/04/2025
A study on the effects of a modified Atkins diet in patients with multiple sclerosis reveals significant changes in immune cell metabolism and anti-inflammatory responses, suggesting the potential for dietary interventions in multiple...
A study on the effects of a modified Atkins diet in patients with multiple sclerosis reveals significant changes in immune cell metabolism and anti-inflammatory responses, suggesting the potential for dietary interventions in multiple...
A study on the effects of a...
03/04/2025
First Report Managed Care
Conference Coverage
MSDA Test Helps Guide Multiple Sclerosis Treatment Decisions, Study Finds
02/28/2025
The MS Disease Activity test helps guide treatment decisions in multiple sclerosis based on objective changes in treatment plan and clinician reported impact, according to a study presented at the 2025 ACTRIMS Forum.
The MS Disease Activity test helps guide treatment decisions in multiple sclerosis based on objective changes in treatment plan and clinician reported impact, according to a study presented at the 2025 ACTRIMS Forum.
The MS Disease Activity test...
02/28/2025
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use